Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives $11.50 Consensus Target Price from Analysts

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has been assigned an average recommendation of “Buy” from the ten analysts that are presently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and four have given a strong buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $11.50.

CATX has been the topic of several analyst reports. B. Riley lowered their price target on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, November 11th. UBS Group reiterated a “buy” rating and issued a $7.00 target price (down previously from $18.00) on shares of Perspective Therapeutics in a report on Friday, November 21st. Finally, BTIG Research began coverage on shares of Perspective Therapeutics in a research report on Friday, October 10th. They set a “buy” rating and a $14.00 target price for the company.

Perspective Therapeutics Stock Up 33.5%

CATX stock opened at $5.06 on Thursday. The firm has a 50 day moving average of $2.69 and a two-hundred day moving average of $3.13. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $6.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.66 and a quick ratio of 8.66.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its earnings results on Monday, November 10th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.02). Perspective Therapeutics had a negative return on equity of 40.03% and a negative net margin of 9,841.86%.The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.21 million. On average, sell-side analysts predict that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds have recently modified their holdings of the business. Nicholson Wealth Management Group LLC increased its holdings in shares of Perspective Therapeutics by 0.3% during the 2nd quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company’s stock worth $5,553,000 after purchasing an additional 5,000 shares during the period. Trueblood Wealth Management LLC grew its position in Perspective Therapeutics by 210.6% during the second quarter. Trueblood Wealth Management LLC now owns 69,061 shares of the company’s stock worth $238,000 after buying an additional 46,825 shares in the last quarter. Mariner LLC increased its stake in Perspective Therapeutics by 33.6% during the third quarter. Mariner LLC now owns 86,116 shares of the company’s stock valued at $295,000 after acquiring an additional 21,653 shares during the period. Mercer Global Advisors Inc. ADV raised its holdings in Perspective Therapeutics by 81.8% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 29,275 shares of the company’s stock valued at $100,000 after acquiring an additional 13,168 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares during the period. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.